Figure 1.

Distribution of prescription claims within Medicare Part D among urologists and nonurologist providers of medications for BPH, ED and OAB. A, among BPH medications urologists were much more likely to prescribe silodosin, alfuzosin and tamsulosin/dutasteride, while non-urologists prescribed significantly more doxazosin and terazosin. Not shown in figure 1 for clarity, due to lower prescription rates, are brand-name tamsulosin (3,722 claims or 0.1% among urologists and 5,090 claims or 0.04% among nonurologists) and brand-name alfuzosin (1,757 claims or 0.04% among urologists and 1,194 claims or 0.01% among nonurologists). Urologists also prescribed more tamsulosin, while rates were overall quite similar between finasteride and dutasteride. B, among ED medications urologists were more likely to prescribe tadalafil while nonurologists were more likely to prescribe sildenafil, and rates of prescription for vardenafil were low in both groups. C, among OAB medications nonurologists were more likely to prescribe oxybutynin and tolterodine, while urologists had higher prescription rates for solifenacin, mirabegron, fesoterodine, trospium and darifenacin.